GlassScriptPhysician profile
George Nicholas Vavilis
NPI 1457791063
$6,904.34
in general payments reported to CMS, 2019-2025
46 companies · $1,097 in 2025
The $1,097 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $646 · 2020: $470 · 2021: $668 · 2022: $866 · 2023: $1,219 · 2024: $1,939 · 2025: $1,097.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,254.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $808.98 | 2019-2025 | Omnipod |
| Amgen INC. | $674.59 | 2020-2025 | Evenity, Tepezza, Prolia |
| Novartis Pharmaceuticals Corporation | $644.10 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $620.26 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $463.05 | 2019-2025 | Verquvo, Gardasil 9, Belsomra |
| Novo Nordisk INC | $393.28 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $306.96 | 2021-2024 | Freestyle Libre 3 |
| Lilly USA, LLC | $235.78 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Mannkind Corporation | $230.22 | 2019-2024 | Afrezza |
| Abbvie INC. | $228.47 | 2019-2025 | Synthroid |
| Daiichi Sankyo INC. | $199.26 | 2021-2024 | Injectafer |
| Xeris Pharmaceuticals, INC. | $175.34 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Amneal Pharmaceuticals LLC | $171.65 | 2019-2025 | Unithroid |
| Medtronic, INC. | $140.67 | 2021-2025 | Minimed 780g |
| Corcept Therapeutics | $130.20 | 2022-2024 | Korlym |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Vavilis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.